Lack of association of SDF-1 3′ A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 3, 2005, Pages 276-279

  Vidal, Francesc ^a   Peraire, Joaquim ^a   Domingo, Pere ^b   Broch, Montserrat ^a   Knobel, Hernando ^c   Pedrol, Enric ^d   Dalmau, David ^e   Viladés, Consuelo ^a   Sambeat, Antònia ^b   Gutiérrez, Cristina ^a   Richart, Cristóbal ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

CCR5 32; Genetic polymorphism; HIV 1 infection; Long term nonprogressors; SDF 1 3 A

Indexed keywords

STROMAL CELL DERIVED FACTOR 1;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTANT; PRIORITY JOURNAL;

ADULT; ALLELES; CHEMOKINES, CXC; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HOMOZYGOTE; HUMANS; MALE; POLYMORPHISM, GENETIC; SPAIN;

EID: 27444441921     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000176653.89769.4d     Document Type: Article

References (24)

1. Moore JP, Kitchen SG, Pugach P, et al. The CCR5 and CXCR4 coreceptors-central understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004;20:111-126.
2. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996;382:833-835.
3. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science. 1998;279:389-393.
4. Shirozu M, Nakano T, Inazawa J, et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 1995;28:495-500.
5. van Rij RP, Broersen S, Goudsmith J, et al. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS. 1998;12(Suppl):F85-F90
6. (erratum: AIDS. 2002;16:2239).
7. Mummidi S, Ahuja SS, González E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998;4:786-793.
8. Meyer L, Magierowska M, Hubert JB, et al. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. AIDS. 1999;13:624-626.
9. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis. 2003;188:1461-1472.
10. Ioannidis JPA, Rosenberg PS, Goedert JJ, et al. Effects of CCR5, CCR2-641, and SDF-1 3 ′ A alleles of HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782-795.
11. Mikhail M, Wang B, Saksena NK. Mechanisms involved in non-progressive HIV disease. AIDS Rev. 2003;5:230-244.
12. Hendel H, Henon N, Lebaunec H, et al. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr. 1998;19:381-386.
13. Balotta C, Bagnarelli P, Corvasce S, et al. Identification of two distinct subsets of long-term non-progressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. J Infect Dis. 1999;180:285-289.
14. Magierowska M, Theodorou I, Debré P, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood. 1999;93:936-941.
15. Castro KG, Ward JW, Slutsker L, et al. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report MMWR. 1992;41:961-962.
16. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 2000;14:821-826.
17. Mazzuchelli R, Corvasce S, Violin M, et al. Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals. J Biol Regul Homeost Agents. 2001;15:265-271.
18. Tresoldi E, Romiti ML, Boniotto M, et al. Prognostic value of the stromal cell-derived factor 1 3′ A mutation in pediatric human immunodeficiency virus type 1 infection. J Infect Dis. 2002;185:696-700.
19. Soriano A, Martínez C, Garcia F, et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3′ A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis. 2002;186:922-931.
20. Mulherin SA, O'Brien TR, Ioannidis JPA, et al. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS. 2003;17:377-387.
21. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29:306-309.
22. Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common diseases. Nat Genet. 2003;33:177-182.
23. Barber Y, Rubio C, Fernández E, et al. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type I disease progression among HIV-seropositive injection drug users. J Infect Dis. 2001;184:1279-1288.
24. Schinkel J, Langendam MW, Coutinho RA, et al. No evidence for an effect of the CCR5Δ32/+ and CCR22b641/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis. 1999;79:825-831.